Web: www.taiclone.com
Tel: +886-2-2735-9682
Email: order@taiclone.com

GSK2636771

Catalog No: tcsc0747

Available Sizes

Size: 5mg

Size: 10mg

Size: 50mg

Size: 100mg

Specifications

CAS No:
1372540-25-4

Formula:
$C_{22}H_{22}F_3N_3O_3$

Pathway:
PI3K/Akt/mTOR

Target:
PI3K

Purity / Grade:
>98%

Solubility:
DMSO : 10.6 mg/mL (24.46 mM; Need ultrasonic and warming)

Observed Molecular Weight:
433.42

Product Description

GSK2636771 is a potent, selective and oral inhibitor of **PI3Kβ** with a $\mathbf{K_i}$ of 0.89 nM and an $\mathbf{IC_{50}}$ of 5.2 nM, showing 900-fold

Web: www.taiclone.com
Tel: +886-2-2735-9682
Email: order@taiclone.com

selectivity over p110α and p110γ, and 10-fold selectivity over p110δ isoforms.

In Vitro: GSK2636771 treatment causes cell viability significantly more decreased in the control cells (p110β-reliant PTEN-deficient PC3 prostate and BT549 and HCC70 breast cancer cell lines) than in PTEN-mutant and PTEN wild-type EEC cells. Inhibition of p110β by GSK2636771 or AZD6482 leads to a marked decrease of AKT phosphorylation only in the control prostate and breast cancer cell lines, whereas only marginal effects on AKT activation are observed in EEC cells[1].

In Vivo: GSK2636771 is a p110β inhibitor, and the p110β primes cells for response to growth factor stimulation. While p110β inhibition suppresses cell and tumor growth, dual targeting of p110α/β enhances apoptosis and provides sustained tumor response in mice model[2].